Omeros (NASDAQ:OMER) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Omeros Corporation (NASDAQ:OMER) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.21 and traded as high as $12.14. Omeros shares last traded at $11.69, with a volume of 790,665 shares.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, HC Wainwright increased their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Stock Performance

The firm’s 50-day moving average price is $12.30 and its two-hundred day moving average price is $8.27. The firm has a market cap of $845.84 million, a PE ratio of -5.91 and a beta of 2.44.

Insider Transactions at Omeros

In other news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. UBS Group AG lifted its stake in Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after acquiring an additional 666,357 shares during the period. JPMorgan Chase & Co. raised its position in Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the last quarter. State Street Corp boosted its stake in Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.